Oculis Holding AG Ordinary shares (OCS) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Oculis Holding AG Ordinary shares (OCS) has a cash flow conversion efficiency ratio of -0.081x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-15.98 Million) by net assets ($196.29 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See OCS equity financing ratio to measure how much of total assets are equity-financed.
Oculis Holding AG Ordinary shares - Cash Flow Conversion Efficiency Trend (2020–2025)
This chart illustrates how Oculis Holding AG Ordinary shares's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore Oculis Holding AG Ordinary shares long-term investment intensity to see how much of total assets are deployed in long-term investments.
Oculis Holding AG Ordinary shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Oculis Holding AG Ordinary shares ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Neurogene Inc
NASDAQ:NGNE
|
-0.110x |
|
Guangdong Mingzhu Group Co Ltd
SHG:600382
|
0.035x |
|
JINXIN FERT.GRP HD-00001
F:3NX
|
N/A |
|
Mengtian Home Group Inc.
SHG:603216
|
N/A |
|
Yabao Pharmaceutical Group Co Ltd
SHG:600351
|
0.047x |
|
Jana Small Finance Bank
NSE:JSFB
|
-0.575x |
|
Shenzhen Absen Optoelectronic Co Ltd
SHE:300389
|
0.210x |
|
Beijing Navigation Control Technology Co. Ltd.
SHG:688282
|
N/A |
Annual Cash Flow Conversion Efficiency for Oculis Holding AG Ordinary shares (2020–2025)
The table below shows the annual cash flow conversion efficiency of Oculis Holding AG Ordinary shares from 2020 to 2025. For the full company profile with market capitalisation and key ratios, see market cap of Oculis Holding AG Ordinary shares.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $196.29 Million | $-62.22 Million | -0.317x | +51.03% |
| 2024-12-31 | $73.38 Million | $-47.50 Million | -0.647x | -12.67% |
| 2023-12-31 | $93.73 Million | $-53.84 Million | -0.574x | -324.51% |
| 2022-12-31 | $-97.99 Million | $-25.07 Million | 0.256x | +12.82% |
| 2021-12-31 | $-60.95 Million | $-13.82 Million | 0.227x | -17.69% |
| 2020-12-31 | $-43.65 Million | $-12.03 Million | 0.276x | -- |
About Oculis Holding AG Ordinary shares
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic, neuro-ophthalmic, and neurological diseases in Switzerland and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candida… Read more